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Abstract 36 
Objectives Few studies have assessed risk and impact of lymphedema among women treated 37 
for endometrial cancer. We aimed to quantify cumulative incidence of, and risk factors for 38 
developing lymphedema following treatment for endometrial cancer and estimate absolute 39 
risk for individuals. Further, we report unmet needs for help with lymphedema-specific 40 
issues.   41 
Methods Women treated for endometrial cancer (n=1243) were followed-up 3-5 years after 42 
diagnosis; a subset of 643 completed a follow-up survey that asked about lymphedema and 43 
lymphedema-related support needs. We identified a diagnosis of secondary lymphedema 44 
from medical records or self-report. Multivariable logistic regression was used to evaluate 45 
risk factors and estimates.  46 
Results Overall, 13% of women developed lymphedema. Risk varied markedly with the 47 
number of lymph nodes removed and, to a lesser extent, receipt of adjuvant radiation or 48 
chemotherapy treatment, and use of nonsteroidal anti-inflammatory drugs (pre-diagnosis). 49 
The absolute risk of developing lymphedema was >50% for women with 15+ nodes removed 50 
and 2-3 additional risk factors, 30-41% for those with 15+ nodes removed plus 0-1 risk 51 
factors or 6-14 nodes removed plus 3 risk factors, but ≤8% for women with no nodes 52 
removed or 1-5 nodes but no additional risk factors. Over half (55%) of those who developed 53 
lymphedema reported unmet need(s), particularly with lymphedema-related costs and pain.  54 
Conclusion Lymphedema is common, experienced by one in eight women following 55 
endometrial cancer. Women who have undergone lymphadenectomy have very high risks of 56 
lymphedema and should be informed how to self-monitor for symptoms. Affected women 57 
need greater levels of support.  58 
 59 
Key Words lower limb lymphedema, endometrial cancer, risk factors, unmet needs.   60 
61 
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Introduction 62 
Endometrial cancer is the most common malignancy of the female genital tract in developed 63 
countries [1].  Most women (80%) are diagnosed with early stage, low grade tumors, and 64 
have good prognosis (> 90% survival at 5-years) [2]. There are currently no universally 65 
accepted guidelines for the management of women with endometrial cancer. While most 66 
women undergo a hysterectomy and bilateral salpingo-oophorectomy, both the surgical 67 
approach (abdominal, vaginal, laparoscopic, robotic) and extent of surgery vary substantially. 68 
Pelvic with or without para-aortic lymphadenectomy and omentectomy may be performed 69 
depending partly on the stage and grade of the cancer, but also on individual surgeon practice 70 
and patient factors. Patients at increased risk of recurrence might be offered post-operative 71 
radiotherapy in the form of vaginal vault brachytherapy or pelvic external-beam radiotherapy 72 
or, less commonly, chemotherapy [3]. Although often used, randomised trials have indicated 73 
no survival advantage with lymphadenectomy [4] or adjuvant radiotherapy [5] in women with 74 
early-stage disease at intermediate or high risk of recurrence. An increased rate of 75 
lymphedema (chronic lower-limb swelling) has been reported for women who received a 76 
pelvic lymphadenectomy [4]. 77 
 78 
Lymphedema is characterized by increases in extracellular fluid [6]. Secondary lymphedema 79 
presents as swelling of the limbs following cancer treatment [7]. Little is known about lower 80 
limb lymphedema following gynaecological cancer treatment [8]. Incidence rates of lower 81 
limb lymphedema in women following endometrial cancer have been reported between 1-82 
18%, but these figures are mostly based on retrospective chart audits [9-11] that are likely to 83 
under-report cases, case-control studies with select patient groups who underwent particular 84 
surgical procedures [12, 13], studies at a single site [7, 9, 11-14] and studies with modest 85 
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numbers (n=141-243) [7, 15]. Studies assessing risk factors for lymphedema following 86 
endometrial cancer are subject to the same research shortcomings.  87 
 88 
The impact of lower limb lymphedema can be significant including physical discomfort, pain, 89 
and reduction in mobility, body image issues, sexuality issues and distress [15, 16]. The 90 
specific supportive care needs of women with lower limb lymphedema have only been 91 
looked at in one previous study of women with a mix of gynaecological cancer subtypes, of 92 
which only 20 women had lymphedema diagnosed following endometrial cancer [15].  93 
 94 
We therefore undertook a large population-based study to assess lymphedema incidence and 95 
key personal, behavioral and clinical risk factors of post-treatment lymphedema among 96 
women with endometrial cancer and to estimate absolute risk for individuals. Further, we 97 
report the proportion of women with unmet needs for help with lymphedema-specific issues.   98 
 99 
Methods 100 
 101 
Participants and procedures 102 
The study was approved by the Ethics Committee of QIMR Berghofer Medical Research 103 
Institute and all participating hospitals. Participants provided informed consent for each 104 
round of data collection.  105 
 106 
Women newly diagnosed with primary endometrial cancer between May 2005 and December 107 
2007 were recruited for the Australian National Endometrial Cancer Study (ANECS), an 108 
Australia-wide, population-based case-control study. Full details of study design and 109 
participant recruitment have been reported previously [17, 18]. In brief, eligible women were 110 
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aged 18-79 years and of the 2192 eligible women who were invited to participate, 1399 111 
(64%) completed a telephone interview and form the ANECS cohort.  112 
 113 
During 2009-2011, which coincided with a minimum of 3 years and up to 5 years after 114 
participants’ original diagnosis, information about treatment and outcomes, including a 115 
diagnosis of lymphedema (if recorded), was abstracted from the medical records of the full 116 
ANECS cohort (n=1399). ANECS women were also recontacted and asked to complete a 117 
self-administered questionnaire regarding their current lifestyle and quality of life, as well as 118 
lower limb lymphedema symptoms and diagnosis, and lymphedema-specific supportive care 119 
needs. Of the 1399 ANECS participants, 116 had died, 258 chose not to participate in the 120 
follow-up questionnaire; 356 could not be contacted by phone or mail; and 26 women (or a 121 
family member) stated that they were too sick. The remaining 643 women (50%) responded 122 
to the follow-up questionnaire.  123 
 124 
We combined medical records data (n=1140 with recorded lymphedema status) and self-125 
report data (n=643) of a diagnosis for lymphedema for our risk factor analysis. Together this 126 
provided information about lymphedema status on 1243 women or 89% of the cohort; the 127 
remaining 156 women were excluded as they did not complete the ANECS follow-up 128 
questionnaire and information about their lymphedema status was not recorded within their 129 
medical record (n=152), or they had been diagnosed with primary lymphedema before 130 
undergoing surgery for endometrial cancer (n=4).  131 
 132 
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Measures    133 
Outcome measures:  134 
Lymphedema status: Within the ANECS follow-up questionnaire, we used previously 135 
developed questions that asked ‘since being treated for endometrial cancer have you (a) 136 
experienced swelling in your legs, feet or groin? and (b) been told by a doctor or other health 137 
professional that you have lymphedema?’ and, if yes, ‘When were you diagnosed?’ [15]. 138 
Trained research nurses also accessed women’s medical records a minimum of 3 years after 139 
diagnosis to abstract detailed information regarding treatment and all follow-up visits 140 
including the reason for the visit and any symptoms present. Women who self-reported 141 
lymphedema on the follow-up questionnaire or who had a report of lymphedema in their 142 
medical record were classified as having lymphedema.  143 
 144 
Lymphedema-specific supportive care needs: Women who completed the ANECS follow-up 145 
questionnaire and self-reported having lymphedema were asked a further set of eight 146 
lymphedema-specific supportive care need items. These items [15] asked participants to 147 
indicate their level of need for help with each item on a 5-point scale where 1 = not 148 
applicable (no need), 2 = satisfied (need was met), 3 = low unmet need, 4 = moderate unmet 149 
need and 5 = high unmet need. 150 
 151 
Potential lymphedema risk factor variables measured: 152 
Information about personal and behavioral factors relating to the period one year prior to 153 
endometrial cancer diagnosis was collected via interview at recruitment to ANECS. 154 
Information included: age, marital status, education, income, employment status, smoking 155 
status (current, ex, never), number of full-term pregnancies, age at menopause, history of 156 
common comorbidities (including type 1 and 2 diabetes, hypertension and breast cancer) and 157 
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use of common medications (average use over the last five years of aspirin, acetaminophen 158 
and nonsteroidal anti-inflammatory drugs (NSAIDs)). Physical activity was assessed by two 159 
items asking about how many times per week participants did (a) strenuous and (b) moderate 160 
physical activity for at least 20 minutes in their leisure time. This was then coded based on 161 
previously established classification [19, 20] into a three-level physical activity index. We 162 
also used women’s postcode at diagnosis to classify the area they lived according to the 163 
Accessibility/Remoteness Index of Australia (ARIA) [21] and Socio-Economic Indexes for 164 
Areas (SEIFA) [22]. Body mass index (BMI, kg/m2) was derived from self-reported weight 165 
one year before cancer diagnosis and height at diagnosis, and grouped into underweight 166 
(<18.5), normal weight (18.5–24.9), overweight (25.0–29.9), moderately obese (30.0-34.9), 167 
severely obese (35.0-39.9) and very severely obese (≥40.0).  168 
 169 
Clinical variables included: Information on histological subtype (type 1 = low grade 170 
endometrioid +/- mucinous cancers; type 2 = high grade endometrioid, serous, clear cell or 171 
carcinosarcoma), grade (level of differentiation) of the cancer, total number of lymph nodes 172 
removed/positive, number of pelvic lymph nodes removed/positive and number of paraaortic 173 
lymph nodes removed/positive was collected from pathology reports shortly after diagnosis 174 
as part of the initial ANECS data collection. Information about FIGO (2009) stage of disease 175 
(I-IV), primary treatment (including surgery type, chemotherapy, radiation therapy), 176 
recurrence and subsequent treatments (chemotherapy and radiation therapy) was abstracted 177 
from women’s medical records during the clinical follow-up.  178 
 179 
Statistical methods 180 
Binary logistic regression was used to evaluate the association between potential risk factors 181 
and lymphedema. Age and any factors with a univariate p-value <0.2 were retained for 182 
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multivariable modeling. Two multivariable models were fitted. The first model was mutually 183 
adjusted for all other potential risk factors retained following univariate analysis. The second 184 
model used backwards elimination to include only those risk factors with a p-value <0.05 or 185 
those that were of clinical interest (i.e. age and radiation therapy). Consistency analyses (a) 186 
restricting to women in the ANECS follow-up study and (b) using only a diagnosis of 187 
lymphedema when reported in the medical records revealed similar point estimates to the 188 
final main model (data not shown). We initially considered radiation and brachytherapy 189 
separately (none, external beam ± brachytherapy and brachytherapy alone) but collapsed this 190 
to any radiation yes/no in final models as the association with lymphedema did not differ by 191 
type of radiation (p=0.6). We also modeled radiation and chemotherapy (yes, no) as separate 192 
variables, with and without an interaction term, and then as a single four-level variable (no 193 
adjuvant treatment/radiation alone/chemotherapy alone/radiation+chemotherapy). We also 194 
explored the interaction between radiation therapy and number of lymph nodes removed as 195 
some research has indicated the combination of external beam radiation and 196 
lymphadenectomy is a risk factor for lymphedema [10].  197 
 198 
Estimates of absolute risk of developing lymphedema were generated by transforming odds 199 
ratios to probabilities for the combinations of the significant risk factors in the final logistic 200 
regression model. The sensitivity of different combinations of risk factors for identifying 201 
women who would go on to develop lymphedema was also estimated. 202 
 203 
Among women with diagnosed lymphedema who completed the supplementary 204 
lymphedema-specific need items, the proportion of women experiencing moderate-to-high 205 
unmet need was assessed for each item.  206 
 207 
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Results 208 
 209 
Participants’ characteristics 210 
The mean age of women at endometrial cancer diagnosis was 61 years (SD = 9), most (70%) 211 
were married or living with their partner, about half (48%) had completed further education 212 
after high school and16% used NSAIDs prior to their cancer diagnosis. The majority (85%) 213 
were diagnosed with stage I disease, about three-quarters (78%) had low grade endometrioid 214 
tumors, two-thirds (65%) had a laparotomy, half (52%) had lymph nodes removed and, while 215 
two-thirds (67%) of women received no adjuvant treatment, 12% received brachytherapy 216 
alone, 10% external beam radiation alone or with brachytherapy, 4% chemotherapy alone and 217 
6% radiation in combination with chemotherapy therapy (Table 1).  218 
 219 
Overall, 34% (n=461) of women received surgery without lymph node dissection or adjuvant 220 
treatment, 8% (n=114) had surgery and adjuvant treatment only, 25% (n=343) had surgery 221 
and lymph nodes removed but no adjuvant treatment, and 20% (n=277) had surgery with 222 
lymph node dissection and adjuvant treatment. The median number of lymph nodes removed 223 
increased significantly with disease stage (median 0, 6 and 10 nodes for stage I, II and III/IV, 224 
respectively, p<0.001) and decreased with increasing BMI (median 6, 5, 1 and 0 nodes for 225 
normal, overweight, moderately and severely obese, respectively, p<0.001). 226 
 227 
Cumulative incidence and onset of lymphedema 228 
Overall, 13% (95% confidence interval 11%–15%) of women were diagnosed with 229 
lymphedema within the 3 to 5 year follow-up period: 2.5% (n=31) from self-report only (4 of 230 
these women did not have lymphedema status recorded in their medical record), 7.5% (n=93) 231 
from medical records only (66 of these women did not complete the follow-up questionnaire) 232 
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and 2.9% (n=36) from both sources. The discordance among women with data from both 233 
sources was 10% (n=54/531). There were no statistically significant differences in the 234 
personal or clinical characteristics of the women based on the source of their lymphedema 235 
diagnosis.  236 
 237 
The median time to lymphedema diagnosis was 7 months after surgery for endometrial 238 
cancer and up to 4 years and 8 months. Forty-four percent were diagnosed between 0-6 239 
months, 68% within the first year, 83% within the first two years and 92% within the first 240 
three years after endometrial cancer surgery (Figure 1). 241 
  242 
Risk factors for developing lymphedema 243 
Table 1 shows that women who were severely obese (BMI > 40kg/m2) had a significantly 244 
lower risk of being diagnosed with lymphedema while those with more advanced disease, 245 
higher grade or serous/clear cell histology, who underwent laparotomy, had a greater number 246 
of lymph nodes removed, or received adjuvant chemotherapy and/or external beam radiation 247 
or brachytherapy were more likely to be diagnosed with lymphedema. There was also a 248 
suggestion that the small numbers of women aged less than 50 years or single might be at 249 
lower risk and those who reported taking NSAIDs prior to their cancer diagnosis at higher 250 
risk of lymphedema (p<0.15). 251 
 252 
Many of these factors were, however, highly correlated and Table 2 shows the associations 253 
before and after adjustment for other potential risk factors. By far the strongest risk factor for 254 
lymphedema was the number of nodes removed at surgery with a 3-fold increase in risk 255 
associated with removal of 1-5 nodes increasing to 19-fold for women with 15 or more nodes 256 
removed. Smaller increases were seen for women treated with chemotherapy or who used 257 
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NSAIDs prior to cancer diagnosis and, non-significantly, for older women and those treated 258 
with radiation. Although the association with radiation treatment was attenuated and became 259 
non-significant after adjustment for number of nodes removed or chemotherapy, these 260 
variables were all highly correlated so we explored the relation between them further. The 261 
association between radiation and lymphedema did not differ significantly by number of 262 
lymph nodes removed (p=0.9). Similarly, there was no statistically significant interaction 263 
between receipt of radiation and chemotherapy (p=0.5) suggesting both forms of adjuvant 264 
treatment may increase a woman’s risk of developing lymphedema with the greatest risk for 265 
those who received both (n=90, adjusted OR 2.3, CI 1.3-4.1, p=0.003 compared to those who 266 
had no adjuvant treatment). The strong inverse association with BMI in unadjusted models 267 
was no longer seen after adjustment as obese women were less likely to have nodes removed 268 
or receive adjuvant treatment. 269 
   270 
Estimates of absolute risk of developing lymphedema  271 
Table 3 shows a woman’s personal risk of developing lymphedema based on the number of 272 
nodes she had removed and the number of other risk factors she had. The risk factors 273 
considered were treatment with chemotherapy, radiation or use of NSAIDs; we did not 274 
include older age because the vast majority of women (~90%) were over the age of 50. The 275 
risk was >50% for women who had 15 or more nodes removed and 2-3 additional risk 276 
factors, dropping to 30-41% for women with ≥15 nodes removed and 0-1 other risk factors or 277 
6-14 nodes removed and 3 additional risk factors in comparison to a risk of ≤8% for women 278 
who had no nodes removed or up to 5 nodes removed but no other risk factors.   279 
 280 
Sensitivity of risk variables for predicting who will develop lymphedema  281 
If all women who had any lymph nodes removed at surgery were followed-up for 282 
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lymphedema, 90% of lymphedema cases would be identified (sensitivity). This was the 283 
simplest model requiring follow-up of 52% of women with 1 case of lymphedema identified 284 
for every 5 women followed. If only women with >5 or 15+ lymph nodes removed were 285 
followed, this would reduce sensitivity to 82% and 51%, respectively, while reducing the 286 
proportion of women requiring follow-up to 41% and 17%, respectively. If all women who 287 
had nodes removed, chemotherapy or radiation therapy or who used NSAIDs were monitored 288 
this would have required follow-up of 68% of the cohort to identify 96% of those who 289 
developed lymphedema.   290 
 291 
Lymphedema-specific supportive care needs   292 
More than half (55%) of the women with self-reported lymphedema conveyed a need (met or 293 
unmet) for help with lymphedema-specific issues, while 29% had at least one moderate to 294 
high level lymphedema-specific need that was unmet (Table 4). In particular, about one-fifth 295 
of women reported a moderate or high unmet need for help with the cost of having 296 
lymphedema and with the pain or discomfort in their legs or groin (Table 4).  297 
 298 
Discussion 299 
This large population-based study provides empirical evidence that one in eight women 300 
(13%) treated for endometrial cancer will subsequently develop lymphedema, most within the 301 
first 2 years after surgery. Our estimate is in the middle of the 8-18% incidence reported in 302 
smaller studies of self-reported lymphedema [7, 14, 15] and much higher than the 1% 303 
reported when medical records were reviewed alone [9]. We found that the number of lymph 304 
nodes removed at surgery was by far the strongest predictor of subsequent lymphedema risk. 305 
While women who had 15 or more lymph nodes removed, typical of a full lymphadenectomy, 306 
had the greatest risk of going on to develop lymphedema (>50%), even those who had only 1-307 
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5 nodes removed had a 3-fold risk of lymphedema compared to women with no nodes 308 
removed. This suggests that although use of sentinel lymph node dissection in place of full 309 
lymphadenectomy might reduce the incidence of lymphedema, it would not remove it 310 
completely. In comparison, the other factors associated with development of lymphedema in 311 
this population, treatment with adjuvant chemotherapy, radiation or use of NSAIDs (reported 312 
use prior to diagnosis), each conferred a more modest additional risk (adjusted odds ratios 313 
1.3-1.7).   314 
 315 
The association between lymph node removal and lymphedema is consistent with both the 316 
gynecological [7, 9, 11, 15] and breast cancer literature [8, 23], however this is the first study 317 
in the gynecological setting to present adjusted estimates of the risk by number of nodes 318 
removed. The association we observed with adjuvant chemotherapy has not been previously 319 
reported, although a recent meta-analysis found chemotherapy to be a risk factor for upper 320 
limb lymphedema among women with breast cancer [23]. Use of chemotherapy differs 321 
greatly between institutions and has only recently become more widespread thus most earlier 322 
studies in the gynecological setting have not considered this as a potential risk factor. 323 
Disentangling these associations is a challenge because of the strong correlations between 324 
number of lymph nodes removed, chemotherapy and radiation therapy, however our data 325 
suggest that, after adjusting for number of lymph nodes removed, radiation and chemotherapy 326 
may both increase risk slightly, with the greatest effect therefore seen for women who receive 327 
both. However, it is also plausible that receipt of chemotherapy in particular is a surrogate for 328 
more advanced disease and thus more extensive treatment overloading the lymph system. 329 
   330 
The apparent increase in risk among women who reported more frequent use of NSAIDs 331 
prior to diagnosis was unexpected. Although we only had information regarding NSAID use 332 
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prior to diagnosis, we hypothesize that NSAID users would continue to use these medications 333 
post-cancer and that this use may adversely influence the lymph system. It is, however, also 334 
possible that this was a chance finding or that NSAID use is a marker for something else, for 335 
example other hip or knee conditions that might lead to lower limb swelling and thus a 336 
diagnosis of lymphedema. Additional studies are required to evaluate this further.  337 
   338 
The other personal, behavioral and clinical factors that we considered were not associated 339 
with lymphedema, including overweight and obesity although this has been previously 340 
reported as a risk for lower limb lymphedema among women with gynaecological cancer [14, 341 
15]. In our study population, overweight and obese women were less likely to develop 342 
lymphedema than those of normal weight because they typically required less aggressive 343 
treatment; this apparent benefit disappeared after adjustment for number of nodes removed.  344 
It is possible that previous studies have found an association of obesity with lymphedema 345 
because they used a cruder measure of lymph nodes removed (yes/no lymphadenectomy [14], 346 
yes/no nodes removed [15]), or because they combined a lymphedema diagnosis with 347 
undiagnosed self-reported swelling [15]. It is also possible the association may depend on the 348 
method of lymphedema measurement as, in the breast cancer setting, a relationship has been 349 
reported when limb circumference was used to diagnose lymphedema, but not when 350 
lymphedema was classified according to self-reported symptoms or bioimpedance 351 
spectroscopy measurement of extracellular fluid [24].  352 
 353 
One strength of our study includes that its large size allowed us to estimate the absolute risk 354 
of secondary lymphedema for individuals and the sensitivity of different combinations of risk 355 
factors for predicting which women treated for endometrial cancer might go on to develop 356 
lymphedema. These results have practical utility that can be used in clinical practice. 357 
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Clinicians could inform their patients of their risk of developing lymphedema and advise 358 
those with an elevated risk about how to self-monitor for symptoms. The strong association 359 
between lymph node dissection and risk of lymphedema suggests that clinicians, as part of 360 
their regular follow-up, may only need to ask women who have had a lymphadenectomy or 361 
adjuvant treatment about whether they have developed any lower limb swelling. If this tiered 362 
approached were to happen consistently across centres, it would identify almost all 363 
lymphedema cases and substantially reduce the numbers requiring follow-up. Women who 364 
self-report persistent limb swelling that cannot be attributed to any other cause could then be 365 
assessed by a lymphedema specialist sooner, when decongestive treatment is potentially more 366 
effective [25]. Lymphedema has no cure but can be successfully managed when properly 367 
diagnosed and treated [26].  368 
   369 
As the total number of women with endometrial cancer increases each year [1] it is important 370 
that health professionals focus on prevention, early detection and optimal care of women with 371 
lymphedema to ensure physical symptoms and psychological stress are minimized [27]. In 372 
the breast cancer setting, women identified the most common unmet need as having a doctor 373 
that was fully informed about lymphedema [28]. Ours is one of only two studies to date to 374 
consider lymphedema-specific supportive care needs among women with endometrial cancer. 375 
Both studies [15] indicate a considerable proportion (≥15%) of women experience a moderate 376 
to high unmet need for help with pain of discomfort in the legs or groin and with the costs of 377 
having lymphedema. However, our study is the first to consider these needs purely among 378 
women with a diagnosis of lymphedema rather than needs reported by symptomatic and 379 
diagnosed lymphedema sufferers [15].   380 
 381 
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This study has a number of limitations. There was some discordance between women who 382 
self-reported vs. medical record reported lymphedema. While we found no statistically 383 
significant differences in the characteristics of these two groups and our consistency analyses 384 
found the same risk factors, this misclassification indicates that neither doctors nor patients 385 
may be particularly good at making the diagnosis and thus a prospective evaluation using 386 
objective measures is needed. Furthermore, participants may self-report other conditions such 387 
as lipedema which may resemble lymphedema, thus we may over-estimate lymphedema.   388 
  389 
In summary, through combined medical records and self-reported data, this large-scale study 390 
provides clinicians with an estimation of how common lymphedema is, and an understanding 391 
of how best to predict who is at risk of it developing following endometrial cancer. This 392 
study also provides estimates of a woman's risk that can be used in clinical practice and 393 
supports a tiered follow-up of lymphedema screening within the first two years of 394 
endometrial cancer treatment for women who had lymph nodes removed. Finally this study 395 
indicates those women who develop lymphedema need affordable management of pain and 396 
discomfort.   397 
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Table 1. Characteristics of participants (n=1243) at diagnosis and incidence of lymphedema 
 n % Lymphedema (%) p-valuea 
Age (years)     
<50 141 11.3 7.8 0.15 
50-65 646 52.0 13.2  
>65 456 36.7 14.0  
Marital Status     
Married / De facto 837 69.8 14.2 0.084 
Divorced / Separated / Widowed 230 19.2 11.7  
Single 133 11.1 7.5  
Education     
High School 646 52.0 13.8 0.53 
Technical College 412 33.1 12.4  
University 185 14.9 10.8  
BMI one year before cancer diagnosis  
   
Normal weight or underweight  304 25.4 16.4 0.005 
Overweight   314 26.3 15.9  
Moderately obese  255 21.3 11.8  
Severely/very severely obese  323 27.0 8.0  
Pre-cancer nonsteroidal anti-inflammatory drug use     
<1/week 1047  84.3 12.0 0.061 
≥1/week 195  15.7 16.9  
Disease stage (FIGO 2009)     
I 1041 85.7 11.2 <0.001 
II 76 6.3 18.4  
III 85 7.0 24.7  
IV 13 1.1 30.8  
Histology     
Grade 1or 2 endometrioid +/- mucinous (Type 1) 964 77.6 9.3 <0.001 
Grade 3 endometrioid (Type 2)b 135 10.9 24.4  
Serous/clear cell (Type 2) 109 8.8 29.4  
Carcinosarcoma (Type 2) 35 2.8 14.3  
Grade     
Well differentiated 653 53.2 7.8 <0.001 
Moderately differentiated 340 27.7 13.2  
Poorly differentiated 235 19.1 26.4  
Surgery type     
Laparotomy 806 65.4 15.4 0.001 
Laparoscopy 351 28.5 8.3  
Other 76 6.2 6.6  
Number of nodes removed     
0 583 48.1 2.7 <0.001 
1-5 130 10.7 9.2  
6-14 293 24.2 16.7  
15+ 205 16.9 38.0  
Adjuvant chemotherapy     
No  1090 88.7 10.9 <0.001 
Yes 139 11.3 28.1  
Adjuvant radiation therapy     
None  872 71.1 9.6 <0.001 
Brachytherapy alone 156 12.7 21.8  
External beam ± brachytherapy 199 16.2 20.6  
Adjuvant treatment     
None  824 67.2 9.1 <0.001 
Brachytherapy alone 141 11.5 20.6  
External beam radiation (± brachytherapy) 119 9.7 12.6  
Chemotherapy alone 48 3.9 18.8  
Chemotherapy + brachytherapy 14 1.1 35.7  
Chemotherapy + external beam radiation 77 6.3 32.5  
Note: some variables have missing data so n does not always equal 1243  
a From chi-squared test  
b Includes women with mixed endometrioid /serous & endometrioid /clear cell cancers where the serous/clear cell component was <10% 
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Table 2. Correlates of lower limb lymphedema 
 Unadjusted  Fully adjusteda  Final adjustedb 
 OR 
(95% CI) 
p-value  OR 
(95% CI) 
p-value  OR 
(95% CI) 
p-value 
Age (years)         
<50 Referent 0.16  Referent 0.77  Referent 0.31 
50-65 1.8 (0.9-3.5)   1.3 (0.6-2.8)   1.6 (0.8-3.3)  
>65 1.9 (1.0-3.8)   1.3 (0.6-3.0)   1.8 (0.8-3.8)  
Marital Status 
        
Married / Defacto Referent 0.09  Referent 0.13    
Divorced / Separated / Widowed 0.8 (0.5-1.3)   0.9 (0.6-1.6)     
Single 0.5 (0.3-1.0)   0.5 (0.2-1.0)     
BMI 1 year before cancer diagnosis  
   
    
Normal weight or underweight  Referent  0.006  Referent  0.65    
Overweight   1.0 (0.6-1.5)   0.9 (0.6-1.6)     
Moderately obese  0.7 (0.4-1.1)   0.9 (0.5-1.6)     
Severely/very severely obese  0.4 (0.3-0.7)   0.7 (0.4-1.2)     
Pre-cancer nonsteroidal anti-
inflammatory drug use  
 
   
    
<1/week Referent  0.062  Referent  0.047  Referent  0.029 
≥1/week 1.5 (1.0-2.3)   1.7 (1.0-2.9)   1.7 (1.1-2.8)  
FIGO (2009) stage at diagnosis         
I Referent  <0.001  Referent  0.98    
II 1.8 (1.0-3.3)   1.0 (0.5-2.1)     
III-IV 2.7 (1.7-4.4)   1.1 (0.5-2.2)     
Histologyc 
    
    
Type 1 Referent  <0.001  Referent  0.074    
High grade endometrioid 3.1 (2.0-4.9)   1.2 (0.7-2.1)     
Type 2 3.4 (2.2-5.2)   1.0 (0.5-1.8)     
Surgery type  
   
    
Laparotomy Referent  0.001  Referent  0.37    
Laparoscopy 0.5 (0.3-0.8)   1.0 (0.6-1.7)     
Other 0.4 (0.2-1.0)   0.5 (0.2-1.4)     
Number of nodes removed         
0 Referent  <0.001  Referent  <0.001  Referent  <0.001 
1-5 3.6 (1.7-7.8)   2.9 (1.2-6.8)   3.1 (1.4-6.9)  
6-14 7.1 (4.0-12.8)   6.3 (3.3-12.0)   6.3 (3.5-11.4)  
15+ 21.8 (12.3-38.5)   17.8 (9.2-34.3)   18.6 (10.3-33.5)  
Adjuvant chemotherapy  
   
    
No  Referent  <0.001  Referent  0.044  Referent  0.031 
Yes 3.2 (2.1-4.8)   2.0 (1.0-3.8)   1.7 (1.1-2.8)  
Adjuvant radiation therapy  
       
No  Referent  <0.001  Referent  0.24  Referent  0.20 
Yes 2.5 (1.8-3.5)   1.3 (0.8-2.1)   1.3 (0.9-1.9)  
OR: odds ratio; CI: confidence interval; p-value for overall significance of factor 
a Adjusted for all variables in the table. 
b Adjusted for age, nonsteroidal anti-inflammatory drugs, number of nodes removed, chemotherapy and radiation therapy 
c Type 1 includes low-grade endometrioid and endometrioid/mucinous cancers; High grade endometrioid includes women with mixed endometrioid/serous & 
endometrioid/clear cell cancers where the serous/clear cell component was <10%; Type 2 includes serous and clear cell cancers and carcinosarcomas.  
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Table 3. Probability an individual woman will develop lower limb lymphedema for combinations of risk factors 
 
 Number of lymph nodes removed 
Number of other risk factorsa 0 1-5 6-14 ≥15 
None 2% 7% 13% 30% 
One only 4% 11% 19% 41% 
Two only  5% 15% 25% 52% 
All three 8% 22% 36% 62% 
Note: Greyscale indicates level of risk: darker equals higher risk  
a Includes adjuvant chemotherapy, adjuvant radiation and nonsteroidal anti-inflammatory drug use (pre-diagnosis). 
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Table 4. Lymphedema-specific supportive care needs reported by women with self-reported diagnosed 
lymphedema 3-5 years after a diagnosis of endometrial cancer  
 
Individual need items 
Total N Survivors with 
moderate-to-high 
unmet need % (n) 
The cost of having lymphedema  63 18% (11) 
Pain or discomfort in the legs or groin  66 17% (11) 
To be more informed about the causes, prevention and treatment of lymphedema  67 14% (9) 
To be given written information about ways to manage symptoms of lymphedema 66 12% (8) 
To be given more help in managing the symptoms of lymphedema 66 11% (7) 
Coping with changes in your self-image as a result of having lymphedema 66 11% (7) 
Managing the symptoms of lymphedema in  the workplace 63 8% (5) 
Doing your daily activities around the home 67 3% (2) 
Totals  Total, % (n) 
Any moderate-to-high unmet lymphedema need(s)  67 28% (19) 
Any unmet lymphedema need(s) 67 40% (27) 
Any met or unmet lymphedema need(s) 67 54% (36) 
Note. Each individual need item has a different number of participants who completed that item. Total scores convert missing values to no need.  
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Figure 1. Time from surgery for endometrial cancer to diagnosis of lymphedema 
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